In univariable and multivariable analyses, age, race, ethnicity, baseline BMI, diabetes diagnosis, breast cancer stage, histology, breast cancer subtype, and menopausal status were not significantly associated with having 5% or greater weight loss at 12 months after GLP-1 RA initiation ( Figure )
The main concerns with GLP-1 agonist drugs include: GI side effects (nausea, diarrhea, vomiting, constipation, abdominal pain) High out-of-pocket cost for those who do not quality under insurance Risk of inadequate nutrition (reduced intake + insufficient nutrition counseling) Significant loss of muscle mass & bone density High discontinuation rates (with lost weight regained) Limited public & clinician knowledge on importance/implementation of nutrition and lifestyle changes Side Effects and Costs of GLP-1 Medications The use of GLP-1 drugs has been associated with numerous side effects, ranging from mild to severe
If your plan has a specific exclusion for weight management medications, a prior authorization or appeal will be denied
Tamura T, Suzuki M, Hayashida K, Kobayashi Y, Yoshizawa J, Shibusawa T, Sano M, Hori S, Sasaki J